Order Article Reprints

Wass R, Hochmair M, Kaiser B, Grambozov B, Feurstein P, Weiß G, Moosbrugger R, Sedlmayer F, Lamprecht B, Studnicka M, et al. Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity. Cancers. 2022; 14(13):3226. https://doi.org/10.3390/cancers14133226

Wass, Romana, Maximilian Hochmair, Bernhard Kaiser, Brane Grambozov, Petra Feurstein, Gertraud Weiß, Raphaela Moosbrugger, Felix Sedlmayer, Bernd Lamprecht, Michael Studnicka, and et al. 2022. "Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity" Cancers 14, no. 13: 3226. https://doi.org/10.3390/cancers14133226

Wass, R., Hochmair, M., Kaiser, B., Grambozov, B., Feurstein, P., Weiß, G., Moosbrugger, R., Sedlmayer, F., Lamprecht, B., Studnicka, M., & Zehentmayr, F. (2022). Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity. Cancers, 14(13), 3226. https://doi.org/10.3390/cancers14133226